Skip to content
  • Career
  • Support
  • Contact Us
Menu
  • Career
  • Support
  • Contact Us
  • Solutions
    • Clinical Services
    • Research Services
  • Get Started
    • Get Set Up
    • Get a Quote
  • Science
    • What We Do
    • How We Do It
    • Why It Matters
    • Our Core Areas
    • Technology
  • News & Events
    • News
    • Events
  • Resources
    • Webinars
    • Publications
    • Whitepapers
    • Report References
    • Media
  • About Us
    • About AMRA
    • The Team
    • Partners & Investors
Menu
  • Solutions
    • Clinical Services
    • Research Services
  • Get Started
    • Get Set Up
    • Get a Quote
  • Science
    • What We Do
    • How We Do It
    • Why It Matters
    • Our Core Areas
    • Technology
  • News & Events
    • News
    • Events
  • Resources
    • Webinars
    • Publications
    • Whitepapers
    • Report References
    • Media
  • About Us
    • About AMRA
    • The Team
    • Partners & Investors
Search
Close
Menu
  • Solutions
    • Clinical Services
    • Research Services
  • Get Started
    • Get a Quote
    • Get Set Up
  • News & Events
    • News
    • Events
  • Science
    • What We Do
    • How We Do It
    • Why It Matters
    • Our Core Areas
    • Technology
  • Resources
    • Webinars
    • Publications
    • Whitepapers
    • Report References
    • Media
  • About Us
    • About AMRA
    • The Team
    • Partners & Investors
  • Career
  • Support
  • Contact Us
  • All Webinars

Whole-Body MRI Composite Scoring in Neuromuscular Disease Research & Muscle Health

  • The recorded webinar will soon be uploaded. Please come back in a couple of days.

You need a link to access the webinar

You will get an access link sent to your e-mail.


    Neuromuscular disorders (NMDs) are generally variably progressing, rare diseases causing devastating skeletal muscle injury resulting in severe disability and even death. In the intensive search for treatments and cures, MRI has emerged as a promising clinical and drug development tool that can detect early disease progression and treatment effects before loss of muscle function or disability can be observed with clinical assessments.

    Muscle atrophy and muscle fat replacement are hallmarks of NMDs. Most NMDs are characterized by heterogeneity in the pattern and timing of muscle involvement among patients. This causes significant variability and leads to challenges in the assessment of potential treatment effects. Recent technical advances have led to the development of muscle biomarkers based on whole-body water and fat separated MRI that can describe the distribution and progression of muscle atrophy and fat replacement with high precision and accuracy. Imaging the whole body enables the identification of a personalized set of affected muscles, decreasing the variability and increasing the sensitivity of efficacy assessment.

    In this webinar, two experts will review techniques for whole-body MRI and its application in NMD clinical research. Technical aspects will be discussed, including:

    • Practical implementation of MRI scanning protocols
    • Image analysis techniques
    • Biomarker definitions
    • How challenges related to multi-site implementation can be addressed

    Further, featured speakers will discuss how measurements from multiple muscles based on a whole-body MRI scan can be combined into composite scores optimized to describe specific aspects of disease onset pattern, functional impairment, and disease progression between scans. Finally, experiences from recent clinical trials in facioscapulohumeral muscular dystrophy (FSHD) will be discussed exemplifying how such composite scores can be used as endpoints.

    Request a recording of this webinar to learn how whole-body MRI can support NMD clinical research.

    Webinar Date
    • 23 November 2021
    Markus Karlsson, PhD
    Clinical Science Lead
    AMRA Medical
    Read more
    Markus Karlsson, PhD

    Clinical Science Lead

    AMRA Medical

    Markus Karlsson, PhD, has over 6 years of research experience in the clinical applications of quantitative MRI. As a clinical scientist at ARMA Medical, he focuses his research on how AMRA’s technical platform can be applied as endpoints in clinical trials for neuromuscular disorders. Before joining AMRA, Markus completed his PhD at Linköping University, writing a thesis on quantitative MRI of the liver.
    Michelle L. Mellion, MD
    Executive Medical Director
    Head of Neuromuscular Clinical Development
    Fulcrum Therapeutics
    Read more
    Michelle L. Mellion, MD

    Executive Medical Director

    , Head of Neuromuscular Clinical Development

    Fulcrum Therapeutics

    Dr. Mellion is an executive medical director and head of neuromuscular clinical development working on therapies for rare neuromuscular diseases at Fulcrum Therapeutics. She graduated from Colgate University with honors in molecular biology and Wake Forest University Medical School. She went on to complete her internship in medicine, residency in neurology and fellowship in clinical neurophysiology at Brown. She is board certified in neurology and clinical neurophysiology. After approximately a decade on the faculty at the Warren Alpert Medical School/Brown University where she conducted her own grant-funded research, she served as director of the clinical neurophysiology fellowship, neurology residency program and was an attending physician at the MDA neuromuscular clinic as well as at her own private general neurology clinic. Following this, Dr. Mellion decided to expand her scope of expertise in the pharmaceutical industry. She transitioned from academia to clinical development at Biogen where she worked on the remyelination program as well as contributed to the development of novel biomarkers. She then co-led the pain program at Vertex Pharmaceuticals. Dr. Mellion has authored and co-authored numerous publications on her research as well as in programs to which she has contributed in industry. She continues to see neuromuscular patients in her clinic affiliated with Tufts University.
    What you will learn
    •
    Advantages of whole-body MRI techniques for NMD research
    •
    Addressing multi-site MRI scanning protocol implementation
    •
    Exploring early disease progression and treatment effects with MRI
    •
    Discuss the heterogenous presentation of most NMDs
    •
    Using composite scores as endpoints in recent FSHD clinical trials
    Who should attend?
    •
    Chief Medical Officer
    •
    Chief Executive Officer
    •
    Neuromuscular Clinicians
    •
    Principal Investigator
    •
    Medical Director
    •
    Research Nurse
    •
    Clinical Director
    •
    Clinical Project Manager
    •
    Imaging Specialist
    •
    Clinical Operations
    •
    Clinical Development Manager
    •
    Physical Therapist
    •
    Occupational Therapist
    •
    Procurement Manager
    •
    Statistician
    •
    Data Manager
    •
    Regulatory Coordinator
    •
    Business Development
    Research Services
    Follow us
    Linkedin Twitter Facebook

    About

    AMRA offers clinical services and research services to support transformative care and vital decision-making, from clinical research to clinical care.

    Contact

    • info@amramedical.com
    • +46 (0) 13 16 26 00
    • Contact Our Support
    • Data Privacy Policy
    • Cookie Policy
    • Data Privacy Policy
    • Cookie Policy

    Newsletter

      © 2023 AMRA Medical AB

      AMRA Medical
      Manage Cookie Consent
      To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
      Functional Always active
      The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
      Preferences
      The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
      Statistics
      The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
      Marketing
      The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
      Manage options Manage services Manage vendors Read more about these purposes
      View preferences
      {title} {title} {title}
      AMRA Medical
      Manage Cookie Consent
      To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
      Functional Always active
      The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
      Preferences
      The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
      Statistics
      The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
      Marketing
      The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
      Manage options Manage services Manage vendors Read more about these purposes
      View preferences
      {title} {title} {title}